VIDEO: Questions remain regarding use of giredestrant, oral SERDs for breast cancer

SAN ANTONIO — In this video, Eleonora Teplinsky, MD, discusses the lidERA trial, presented at San Antonio Breast Cancer Symposium, and what questions and research remain for use of giredestrant in breast cancer.
The phase 3 lidERA trial compared giredestrant (Genentech, Roche), an oral selective estrogen receptor degrader, with standard-of-care chemotherapy among patients with early-stage, hormone receptor-positive, HER2-negative breast cancer.
“A lot will evolve in the coming months and years,” Teplinsky, head of breast and gynecologic medical oncology at Valley-Mount Sinai

Surge in serotonin points to new treatment target for schizophrenia

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has provided the first direct evidence that schizophrenia is associated with a greater release of serotonin in the frontal cortex, and demonstrates its link to a greater severity of some of the most disabling symptoms of the disorder.

Simple fruit granola intervention shows promising cardio-renal signals in CKD patients

A single-arm intervention study in Japanese adults with moderate chronic kidney disease found that replacing breakfast with fruit granola for two months lowered systolic blood pressure, reduced LDL-related lipid markers, and decreased a urinary marker of tubular injury. Renal function remained stable, bowel habits improved, and findings were exploratory due to the small, open-label design.